Neoleukin Therapeutics : Corporate Presentation January 2023

Corporate Presentation

January 2023

© Neoleukin Therapeutics. All Rights Reserved.

Forward Looking Statements

Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, expectations and timing of the Company's strategic plans for development, the potential for future clinical development of product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of clinical trials and registration of product candidates, properties of its product candidates, availability of data, the use and sufficiency of its cash resources, and other statements containing the words "anticipate," "believe," "expect," "may," "plan," "project," "potential," "will," "would," "could," "continue," and similar expressions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the ability of the Company to execute on its strategic plan, including success in development of new immunotherapies, the ability to bring any development candidates forward from the research phase into development and approval for clinical trial; its ability to obtain and maintain regulatory approval for any product candidates and the potential safety, efficacy or clinical utility of or any product candidates; cost and timing expectations for the discontinuation of NL-201; further impacts of COVID-19, supply chain disruptions, or other global economic and geopolitical events on its operations; and other factors discussed in the "Risk Factors" section and elsewhere in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and subsequent reports as filed with the Securities and Exchange Commission. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

2	© Neoleukin Therapeutics. All Rights Reserved.

We use protein design to reinvent how therapies are created with a goal

to meaningfully improve patients' lives

Neoleukin is a pioneer in de novo protein development, leveraging computational methods to create new therapies. This new approach has unlimited potential to treat human disease by improving on nature, designing for life. We are building a company with a vibrant and inclusive culture that we believe will make a meaningful impact for patients, our people and our community.

3	© Neoleukin Therapeutics. All Rights Reserved.

Neoleukin: Leader in de novo Protein Therapeutics

2018 2019 2020 2021 2022 FUTURE

NEOLEUKIN	MERGER	FIRST IND
FOUNDED	COMPLETED	SUBMITTED

PHASE 1 TRIAL	MACHINE
INITIATED	LEARNING

EXPAND DE NOVO PROTEIN PIPELINE

Computational methods enable fully de novo protein design

Scientists and technology spun out of University of Washington

NASDAQ listing (NLTX) after merger with Aquinox

More than $140M raised through merger and follow-on offering

First IND of fully de novo protein (NL-201)

Neoleukin scientists create second fully de novo protein (NL- CVX1)

First patients treated	Machine
with fully de novo	learning/neural
protein	network technology
	enables rapid drug
	discovery

Multiple fully de novo molecules expected to enter development in oncology and autoimmune diseases

Innovative approaches to drug delivery, conditional activation, and affinity optimization to improve therapeutic index

4	© Neoleukin Therapeutics. All Rights Reserved.

Leadership Team

Jonathan Drachman, M.D.	Bill Arthur, Ph.D.	Priti Patel, M.D., M.S.
Chief Executive Officer	VP & Head of Research	Chief Medical Officer
P R I O R	P R I O R	P R I O R
CMO, EVP R&D	Seagen	AstraZeneca
Seagen	Merck & Co.	Acerta Pharma

Donna Cochener	Sean Smith
General Counsel, SVP Legal	VP, Finance
P R I O R	P R I O R
HomeStreet	Aptevo Therapeutics
Davis Wright Tremaine	KPMG

5	@Neoleukin Therapeutics. All Rights Reserved.